Shares of this biotech giant have lost 19.2% in the past six months against the industry’s growth of 0.6%. The stock has also ...

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

PGIM shares how the Jennison Health Sciences Fund weathered Q2 volatility by leaning into undervalued innovators. Discover ...

In September 2025, The FDA approved an injectable extended-release risperidone suspension from Amneal Pharmaceuticals, ...

Detailed price information for Puretech Health Plc ADR (PRTC-Q) from The Globe and Mail including charting and trades.

What it also allows us to do is to develop and deploy significant capital into areas where we think there is the potential ...

MT-601 shows a 66% response rate in NHL patients, with 50% achieving a complete response. No dose-limiting toxicities or serious adverse events were reported in the Phase 1 trial. Get the data-driven ...

Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse portfolios. Bristol Myers is focused on discovering, developing and delivering ...

At $24 versus the $89 analyst average price target, Viking trades at a steep discount. While some targets will likely be revised lower, the size of the decline appears excessive for a company with no ...

The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking may decide to take VK2735 (oral form) through ...

Shares of Viking Therapeutics plummeted more than 43% Tuesday after the company revealed poorer-than-expected mid-stage trial data for its experimental weight-loss pill, joining Eli Lilly with similar ...

Positive news from a rival sparked a sympathy rally. This was aided by a positive research note published by an analyst. The clinical-stage biotech, closely watched by some because of its ...